Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Short Report

Oral Acetazolamide after Boston Keratoprosthesis in Stevens Johnson Syndrome

Radhika Kumar, Claes H Dohlman and James Chodosh*

Author Affiliations

Massachusetts Eye and Ear Infirmary, Harvard Medical School, Department of Ophthalmology, Boston, MA, USA

For all author emails, please log on.

BMC Research Notes 2012, 5:205  doi:10.1186/1756-0500-5-205

Published: 30 April 2012

Abstract

Background

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for elevated intraocular pressure.

Findings

Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11 developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction.

Conclusion

Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without serious sequela.

Keywords:
Stevens Johnson syndrome; Toxic epidermal necrolysis; Acetazolamide; Glaucoma